Recro to Present at Stephens Annual Investment Conference
Recro Pharma (NASDAQ: REPH) announced CEO David Enloe will participate in a fireside chat during the Stephens Annual Investment Conference | NASH2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Recro Pharma (NASDAQ: REPH) announced CEO David Enloe will participate in a fireside chat during the Stephens Annual Investment Conference | NASH2021. The conference runs from December 1-3, 2021, and the chat is scheduled for December 3 from 11:00-11:45am CT. Attendees can access a live audio webcast on the company's website, with an archived version available for 30 days post-event. Recro specializes in contract development and manufacturing, focusing on complex challenges in small molecule therapeutic development.
Details
News Market Reaction – REPH
The recorded move for REPH in the trading session of this news was -0.68%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Fireside Chat Webcast Available
SAN DIEGO and GAINESVILLE, Ga., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that its chief executive officer, David Enloe, will participate in a fireside chat as part of the Stephens Annual Investment Conference | NASH2021. Details for the fireside chat are as follows:
- Stephens Annual Investment Conference | NASH2021
- Conference dates: December 1 - 3, 2021
- Presentation details: Recro management will participate in a fireside chat on Friday, December 3, 2021 at 11:00 – 11:45am CT/12:00 – 12:45pm ET. The company will also host 1-on-1 meetings with investors on Friday, December 3, 2021
- Location: Omni Nashville Hotel, Nashville, TN
- Webcast: A live audio webcast of the fireside chat will be available under "Events" in the Investors section of the company's website, https://ir.recropharma.com/events. An archived webcast will be available on the company's website approximately two hours after the event and will be available for 30 days.
About Recro
Recro (NASD: REPH) is a bi-coastal contract development and manufacturing organization (CDMO) with capabilities spanning pre-Investigational New Drug (IND) development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms with a primary focus in the area of small molecules. With an expertise in solving complex manufacturing problems, Recro is a leading CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market.
In addition to our experience in handling DEA controlled substances and developing and manufacturing modified-release dosage forms, Recro has the expertise to deliver on our clients’ pharmaceutical development and manufacturing projects, regardless of complexity level. We do all of this in our best-in-class facilities, which total 145,000 square feet, in Gainesville, Georgia and San Diego, California.
For more information about Recro’s CDMO solutions, visit recrocdmo.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.